• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Epizyme Inc. (Amendment)

    2/10/22 8:11:40 AM ET
    $EPZM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EPZM alert in real time by email
    SC 13G/A 1 tv0825-epizymeinc.htm SCHEDULE 13G/A epizymeinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Epizyme Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  29428V104

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  29428V104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    168,897

    7.  SOLE DISPOSITIVE POWER

    5,750,369

    8.  SHARED DISPOSITIVE POWER

    234,539

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,984,908

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.76%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Epizyme Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    400 Technology Square, 4th floor
    Cambridge, MA 02139

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    29428V104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $EPZM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EPZM

    DatePrice TargetRatingAnalyst
    6/28/2022$1.50Outperform → Market Perform
    Cowen
    6/27/2022Outperform → Neutral
    Wedbush
    3/2/2022$15.00 → $10.00Buy
    HC Wainwright & Co.
    8/10/2021$10.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    8/10/2021$36.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EPZM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

      TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company's Novel, First-in-Class, Oral SETD2 Inhibitor Merger with Ipsen Expected to Close in 3Q 2022 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. "I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product

      8/9/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

      Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement Epizyme stockholders are encouraged to tender their shares to the offer today Regulatory News: Ipsen S.A. ((Euronext: IPN, OTC:IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ:EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Sha

      8/5/22 1:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

      Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini

      6/27/22 1:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Epizyme Inc. (Amendment)

      SC 13G/A - Epizyme, Inc. (0001571498) (Subject)

      9/8/22 4:01:05 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Epizyme Inc.

      SC 13D - Epizyme, Inc. (0001571498) (Subject)

      7/7/22 4:57:01 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Epizyme Inc. (Amendment)

      SC 13D/A - Epizyme, Inc. (0001571498) (Subject)

      6/28/22 8:32:54 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Leadership Updates

    Live Leadership Updates

    See more

    $EPZM
    SEC Filings

    See more
    • Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update

      Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced a clinical update as well as the appointment of Jerald Korn as Chief Operating Officer, reporting to President and Chief Executive Officer, Grant Bogle. "We are excited to welcome Jerald to Epizyme at a pivotal time for the organization," said Mr. Bogle. "Jerald's breadth of experienc

      3/15/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development

      MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board. Kazumi brings experience as both an entrepreneur and an investor within the field of biotechnology. She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi was also a co-founder and CEO of Mitobridg

      12/3/20 3:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Epizyme Inc.

      15-12G - Epizyme, Inc. (0001571498) (Filer)

      8/23/22 5:03:08 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Epizyme Inc.

      EFFECT - Epizyme, Inc. (0001571498) (Filer)

      8/17/22 12:15:13 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Epizyme Inc.

      EFFECT - Epizyme, Inc. (0001571498) (Filer)

      8/17/22 12:15:10 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TAZVERIK issued to EPIZYME INC

      Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

      8/14/24 4:43:30 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for TAZVERIK issued to EPIZYME INC

      Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-4) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 11/16/2023. Application Category: NDA, Application Number: 211723, Application Classification: Labeling

      11/17/23 4:37:35 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Giordano Michael F returned 17,054 shares to the company, closing all direct ownership in the company

      4 - Epizyme, Inc. (0001571498) (Issuer)

      8/16/22 7:03:16 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Goldfischer Carl returned 3,403,005 shares to the company, closing all direct ownership in the company

      4 - Epizyme, Inc. (0001571498) (Issuer)

      8/16/22 7:02:25 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Conroy Kevin T returned 62,318 shares to the company, closing all direct ownership in the company

      4 - Epizyme, Inc. (0001571498) (Issuer)

      8/16/22 7:02:02 PM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Epizyme downgraded by Cowen with a new price target

      Cowen downgraded Epizyme from Outperform to Market Perform and set a new price target of $1.50

      6/28/22 7:22:14 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Epizyme downgraded by Wedbush

      Wedbush downgraded Epizyme from Outperform to Neutral

      6/27/22 9:12:17 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Epizyme with a new price target

      HC Wainwright & Co. reiterated coverage of Epizyme with a rating of Buy and set a new price target of $10.00 from $15.00 previously

      3/2/22 6:34:32 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EPZM
    Financials

    Live finance-specific insights

    See more
    • Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

      Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini

      6/27/22 1:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

      TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study Assessing Tazemetostat in Combination with R2 in Follicular Lymphoma (FL) Updated Data from the Phase 1b Portion of SYMPHONY-1 to be Presented at ASCO; Additional Updates Anticipated in 2H 2022 from Tazemetostat and EZM0414 (SETD2 inhibitor) Studies Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients again

      5/10/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Epizyme Announces Date of First Quarter 2022 Financial Results

      Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5369344. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call. About Epizyme, Inc.

      5/3/22 7:00:00 AM ET
      $EPZM
      Biotechnology: Pharmaceutical Preparations
      Health Care